FORSYTH BARR

WEALTH MANAGEMENT RESEARCH

3 NOVEMBER 2020

Wealth Weekly
Strong Results Not Enough

WEALTH MANAGEMENT RESEARCH
wmr@forsythbarr.co.nz
+64 4 499 7464

Global reporting season ramped up last week with a number of the US large-cap companies that we monitor delivering results. They largely met or beat expectations, but that wasn't enough to send markets higher. Instead global equities suffered their worst week since March, as investors weighed other factors such as surging COVID-19 cases and Tuesday's (Wednesday NZT) US presidential election.

International results not as bad as market movements imply

Several of the technology giants (Apple, Amazon, Alphabet, Facebook and Microsoft) were among the companies that reported results late last week. Amazon's, Alphabet's, Facebook's and Microsoft's September-quarter earnings were strong but management guidance from Amazon and Facebook was more cautious than expected. Apple's result was more mixed as iPhone sales disappointed, although this was probably at least partly due to consumers holding off with purchases until after the recent iPhone 12 launch, and the company didn't provide guidance for the third time in a row. As highlighted in last week's Wealth Weekly, **we continue to like these big tech stocks as core portfolio holdings**. However, given their outstanding performance — both year-to-date and since the COVID-19 lows in mid-March — plus the uncertainty around the US election, we believe it is **prudent to take some profits in these stocks** and to maintain good diversification.

Themes of the week

ResMed reported a very strong quarterly result, which reinforces our expectation that its competitor Fisher & Paykel Healthcare will exceed management's guidance when the company reports on 25 November. The risk-reward in ResMed looks balanced at its current valuation, while F&P Healthcare continues to be expensive.

ANZ Banking Group delivered decent FY20 results that were largely in line with expectations. **Credit quality indicators were positive, albeit core profit concerns were evident**. We agree that the Australian banks look cheap at the moment, but we are not attracted to the long-term outlook as, in our view, the sector continues to face structural headwinds.

Recent New Zealand lending data shows that credit demand remains very muted — except in housing. Despite the Reserve Bank doing everything it can to keep interest rates at ultra-low levels, businesses appear reluctant to borrow more, perhaps understandably given risks to the domestic and global economic outlook.

Looking ahead

There is just a day to go until the US election. Polls remain tilted in Joe Biden's favour but the extraordinary political dynamics in play mean a surprise result, or a contested one, remains a possibility. But beyond the potential short-term market reaction, it'll be worth remembering that **over the longer-term companies, consumers and the economy eventually adapt to political circumstances**. Outside of some industry-specific impacts of policy differences between the candidates (e.g. in energy policy), long-term profit growth and valuations — and therefore equity prices — will be driven more by trends in technology development, demographics and monetary policy than by political and regulatory tinkering.

Earnings season continues this week with reports due from companies including Pushpay, Z Energy, Westpac, Woolworths, National Australia Bank, Qualcomm and Alibaba. NZ King Salmon, Fonterra, Chorus, Spark, Coles, James Hardie and Treasury Wine Estates are among companies holding AGMs this week. The central banks of Australia, Japan, the UK and US will release interest rate decisions, monetary policy statements and/or meeting minutes.

International Reporting Season

Results not as bad as market movements imply

Meeting or beating analysts' expectations hasn't been enough to impress investors this earnings season. Having performed well ahead of results, numerous stocks were sold off after delivering decent earnings, and seemingly getting caught up in the broader market's negative momentum.

Big tech stocks largely delivered

The big technology stocks more or less delivered on expectations. But investors should prepare for potential volatility in the technology sector given the potential threats of stricter regulatory oversight, antitrust reviews, online privacy rules, and higher taxes. We recommend diversifying holdings within the Information Technology sector. Among the big tech stocks we favour Alphabet, Amazon and Apple over Facebook. We continue to like software companies driving digital transformations (salesforce.com, Microsoft), semiconductor companies enabling new technologies such as 5G (Taiwan Semiconductor, Intel, Qualcomm, NVIDIA), and companies providing cyber-security and payment solutions (Palo Alto, Visa).

Alphabet (GOOGL) delivered strong 3Q20 results, beating expectations across the board. Better-than-expected revenue growth in Google Search (+6.5% vs 3Q19) and YouTube (+32.4%) was driven by broad-based increases in advertising spending. GOOGL's core operating income beat was driven by slower headcount growth and lower marketing spending, with management indicating headcount growth will continue to moderate in 4Q20. However, management also pointed to continued uncertainty in the external operating environment potentially impacting 4Q revenue growth. GOOGL's results were well received by the market, with shares trading up amidst the broader sell-off. The key growth drivers of GOOGL's business remain intact, and we expect to see continued scale and growth in its Search, YouTube, and Cloud businesses.

Amazon's (AMZN) 3Q20 result beat estimates at both the revenue and profit line, as strong demand helped drive fulfilment centre operating leverage. Management pointed to higher prime membership renewal rates and engagement, with customers buying more frequently and across more categories. However, operating income guidance for 4Q was soft, with the top end of guidance c.-25% below consensus expectations, due to ongoing COVID-related expenses, additional hiring of employees, and fulfilment expansion. AMZN continues to provide exposure to attractive long-term thematics (eCommerce, cloud computing, online media consumption, digital advertising and AI voice assistants).

Apple (AAPL) reported a mixed 4Q20 result as iPhone weakness and soft Chinese demand offset strong growth in iPads and Macs as work from home and educational demand persisted more than expected. Both revenue and EPS came in ahead of market expectations, but investors were disappointed by the performance of AAPL's iPhone segment where revenues were down -21% vs last year, as consumers likely delayed purchases in anticipation of the new 5G enabled iPhone. AAPL's wearables business continues to experience strong growth, with management noting on the earnings call that their wearables business is now the size of a Fortune 130 company. AAPL did not reinstate guidance — this is the 3rd quarter in a row where this has happened and is likely a disappointment relative to investor expectations. The share price is likely to remain in a holding pattern until the market gains clarity on both the supply chain as well as store closings and re-openings given recent concern around COVID-19.

Facebook (FB) reported better-than-expected 3Q20 results, with total revenue up +22% vs 3Q19, helped by a recovery in brand advertising trends and as offline to online commerce shifts provided tailwinds. Expense growth was also lower-than-expected which supported an earnings beat. In terms of the outlook, management commentary on FY21 revenues highlighted some uncertainties, and the potential for some easing of the COVID-19 user engagement benefits that have been experienced.

Microsoft (MSFT) delivered a strong 1Q21 result, with total revenue of US$37.2bn, ahead of consensus and the company's guidance — driven by consumer Windows, consumer Office and Surface, while commercial cloud/annuity streams were in line or better. Strong profitability was helped by lower expenses and non-operating items. The market is likely to focus on the ability of Microsoft's cloud platform Azure to fight deceleration and continue to drive leverage as it increases in size. Shares are largely fair value in our view, and a strong result was expected by investors so it wasn't surprising to see MSFT's share price pull back a bit with the broader market.

Solid results elsewhere too

Comcast's (CMCSA) 3Q20 results were solid across the board with stronger cable results and smaller-than-expected declines at NBCUniversal and SKY (despite theme park and filmed entertainment operations continuing to be affected by COVID-19). Total revenues were down -4.8% vs 3Q19, a sequential improvement vs 2Q20 results, while EBITDA and free cashflow were well ahead of expectations. CMCSA's Cable Communications segment (52% of group revenue) proved resilient, growing +2.9% vs last year, with 633k net new high-speed internet subscribers, its most ever in a quarter.

Fiserv (FISV) is a provider of financial services technology. For 3Q20 FISV reported above-consensus top- and bottom-line results, with synergies driving margin expansion. The company continued its trend of delivering strong free cashflow, which enabled it to pay down US$769m of debt during the quarter. FISV updated FY20 EPS guidance to "at least 11%" from "at least 10%", with more details on the outlook expected at its investor day on 8 December.

Merck & Co (MRK) reported a decent 3Q20 result with sales and EPS ahead of market estimates. Overall, Pharma revenues beat by +3%, while the Animal Health division was particularly strong, beating consensus by +10%. However, other revenues were significantly below consensus. MRK narrowed revenue guidance to US$47.6–48.6bn (from US$47.2–48.7bn), implying a marginal increase at the mid-point. MRK also lowered its operating expense and tax rate guidance and raised other income, leading to improved EPS guidance of around +4%. MRK's execution and forethought on novel pathways to approval is unique vs its competitors, and its key drug Keytruda (for the treatment of numerous cancers) enjoys a healthy lead time and has a large addressable market. MRK has key franchises in the oncology, cardiovascular, diabetes, infectious diseases, and women's health markets.

Visa (V) delivered 4Q20 results that beat consensus revenue and earnings expectations, despite impacts from weak cross border revenue (which generates much higher fees) due to COVID-19. V did not provide quantitative guidance for FY21, but commentary pointed to an expected strong recovery in 2H21 revenue and ongoing reduction in costs. Spending trends appear to be recovering ahead of expectations, other than those related to travel/entertainment, and we expect V will be able to continue to manage expenses and deliver reasonable earnings growth.

Figure 1. Companies on our watch-list that reported last week

Company Name	Code	Result Date	Price (local)	12-mth Chg	Fcst 1 PE	Fcst 2 PE	PEG	ROE	Div yld	EPS 3yr CAGR
Ping An Insurance	2318	Tue-27-Oct	79.55	-13.3%	9.6x	8.1x	0.7x	23%	3.1%	+14.5%
Fiserv Inc.	FISV	Tue-27-Oct	95.47	-10.7%	21.7x	17.8x	1.2x	8%	0.0%	+17.6%
Eli Lilly & Co	LLY	Tue-27-Oct	130.46	+16.0%	18.2x	16.1x	1.4x	176%	2.5%	+12.8%
3M Co	MMM	Tue-27-Oct	159.96	-6.0%	19.1x	17.3x	2.3x	48%	3.8%	+8.4%
Merck & Co	MRK	Tue-27-Oct	75.21	-11.5%	13.2x	12.0x	1.4x	51%	3.4%	+9.2%
Microsoft	MSFT	Tue-27-Oct	202.47	+40.9%	31.4x	27.4x	2.1x	41%	1.1%	+14.9%
Pfizer	PFE	Tue-27-Oct	35.48	-7.6%	12.4x	11.8x	2.0x	21%	4.4%	+6.3%
Amgen	AMGN	Wed-28-Oct	216.94	-0.5%	13.8x	13.0x	2.4x	70%	3.1%	+5.6%
CME Group	CME	Wed-28-Oct	150.72	-24.3%	21.7x	21.1x	3.3x	9%	4.4%	+6.5%
Gilead Sciences	GILD	Wed-28-Oct	58.15	-10.1%	8.5x	8.6x	7.0x	30%	4.8%	+1.2%
Heineken	HEIA	Wed-28-Oct	76.20	-16.8%	36.2x	20.9x	1.2x	12%	1.8%	+29.5%
Mastercard	MA	Wed-28-Oct	288.64	+3.4%	43.3x	33.1x	2.0x	129%	0.6%	+22.0%
ServiceNow	NOW	Wed-28-Oct	497.57	+96.6%	112.8x	88.0x	3.8x	39%	0.0%	+29.3%
Visa	V	Wed-28-Oct	181.71	+0.4%	36.2x	31.0x	1.9x	40%	0.7%	+18.6%
Takeda Pharmaceutical	4502	Thu-29-Oct	3239.00	-19.0%	7.3x	6.5x	1.0x	7%	5.6%	+7.1%
Apple	AAPL	Thu-29-Oct	108.86	+70.2%	33.6x	28.3x	2.9x	69%	0.9%	+11.7%
Amazon	AMZN	Thu-29-Oct	3036.15	+69.5%	65.0x	51.2x	2.4x	21%	0.0%	+26.9%
Aptiv	APTV	Thu-29-Oct	96.49	+4.5%	75.8x	26.6x	1.1x	11%	0.2%	+66.4%
Activision Blizzard	ATVI	Thu-29-Oct	75.73	+35.7%	23.3x	22.5x	2.9x	14%	0.5%	+8.1%
Baxter International	BAX	Thu-29-Oct	77.57	-0.4%	25.3x	21.6x	1.9x	19%	1.4%	+13.5%
Comcast	CMCSA	Thu-29-Oct	42.24	-5.6%	17.4x	14.3x	1.0x	15%	2.4%	+17.0%
Facebook	FB	Thu-29-Oct	263.11	+35.9%	29.5x	24.1x	1.4x	24%	0.0%	+21.2%
Alphabet	GOOGL	Thu-29-Oct	1616.11	+27.0%	29.0x	25.7x	1.8x	16%	0.0%	+15.8%
Illumina	ILMN	Thu-29-Oct	292.70	-2.6%	64.3x	45.4x	2.4x	19%	0.0%	+26.5%
Sanofi	SAN	Thu-29-Oct	77.37	-5.1%	13.2x	11.4x	1.3x	10%	4.3%	+10.3%
Starbucks	SBUX	Thu-29-Oct	86.96	+4.5%	90.7x	31.8x	1.6x	n/a	2.1%	+57.8%
Yum! Brands	YUM	Thu-29-Oct	93.33	-6.3%	29.3x	24.1x	2.0x	n/a	2.2%	+15.0%
AbbVie	ABBV	Fri-30-Oct	85.10	+4.1%	8.2x	7.0x	0.8x	n/a	6.0%	+10.4%
Charter Communications	CHTR	Fri-30-Oct	603.82	+26.7%	46.4x	27.1x	1.1x	8%	0.0%	+42.6%
Colgate-Palmolive	CL	Fri-30-Oct	78.89	+18.1%	26.6x	24.9x	3.8x	n/a	2.3%	+7.0%

Source: Forsyth Barr analysis

Themes of the Week

Australian Equities

ResMed (RMD) — 1Q21 result

Sleep apnoea and ventilator device maker ResMed (RMD) reported a strong 1Q21 result, well ahead of consensus, underpinned by another quarter of elevated ventilator sales (albeit materially down sequentially), a steady recovery in the sleep business and strong cost control. Key takeaways included that: (1) the sleep industry has fared better than initial expectations, helped by home testing and strong resupply, (2) ventilator demand is slowing materially, (3) the industry price landscape is expected to be benign for at least the next three years, with an alleviation of pressure due to Competitive Bidding Round 2021 being abandoned for sleep products.

We continue to like RMD as a portfolio holding and think the company is well positioned in a growing market with a focus on new applications of its products. However, with shares trading on a 12 mth fwd PE multiple of ~37x, we view the risk-reward proposition as fairly balanced.

ANZ Banking Group (ANZ) — FY20 Results

ANZ delivered decent FY20 results, with cash earnings of $3.76bn in line with expectations. Credit quality indicators were positive. There was a strong improvement in deferred loans and impaired assets fell. Citi lowered its 3-year COVID-19 related loan loss provision estimates for ANZ from 106bps to 90bps and consequently raised its forward EPS by an average of c.+10% and DPS by an average of c.+16%. While asset quality was positive, core profit concerns were evident. Markets income should normalise in FY21, but institutional lending declines will likely continue to be a drag. A strong performance on costs is expected to offset some of the revenue pressures. Citi continues to be bullish on the Australian banks and has a positive view on the credit cycle as well as growth in net interest margins growth. Citi prefers Westpac (WBC), then National Australia Bank (NAB) and ANZ (all three are BUY rated).

We agree that the Australian banks look cheap at the moment, but we are not attracted to the long-term outlook as, in our view, the sector continues to face structural headwinds, and cost cuts are likely to be required to drive an improvement in earnings, as top-line growth potential looks limited.

Fixed Interest

Low borrowing costs doesn't mean everyone is borrowing

The latest lending data from the Reserve Bank of New Zealand (RBNZ) suggests demand for credit (housing aside) remains very muted. This illustrates our questions in recent weeks around the need for looser monetary policy. Is it the level of interest rates reducing the demand for credit? Or is it the ongoing level of uncertainty around the future of not only the local economy but also globally? It would seem the latter is the driver at present, with corporates not willing to extend themselves despite low interest rates until some form of normality returns.

We await further details from the RBNZ around its Funding for Lending (FLP) scheme, which may come via either the Monetary Policy Statement on the 11 November or the Financial Stability Report on 25 November. ANZ CEO Antonia Watson said the ANZ does not need funds from the RBNZ's proposed FLP but that the programme may force deposit rates lower much quicker if banks know that funding is readily available from the RBNZ.

There is plenty for the RBNZ to consider over the next six months.

Figure 2. Annual credit growth



Source: Forsyth Barr analysis, RBNZ

Figure 3. NZ Swap Curve



Source: Forsyth Barr analysis, Refinitiv

Research Worth Reading

New Zealand

Attention to Retail — A More Jolly Christmas...

With Christmas only eight weeks away, the approaching seasonal spend looks to be better than previously anticipated. Retail sales momentum is supported by a buoyant housing market and low interest rates, reducing the incentive to save, while continued border closures allow for a re-allocation of travel spend towards other categories. However, the underlying economic picture remains unclear and we carry a degree of caution into 2021. Within our coverage our preferred consumer retail exposure is Kathmandu (KMD). (Published by Forsyth Barr)

Skellerup (SKL) — Firing on all Cylinders

SKL is on track to deliver strong FY21 earnings growth, well ahead of our prior expectations. SKL issued initial FY21 NPAT guidance, with the mid-point of the range implying growth of +12% on the prior year. Although SKL has re-rated meaningfully in the past six months (18x 12 month forward PE ratio), we continue to see value, with its more resilient earnings base justifying the higher valuation multiples, in our opinion. SKL offers investors an attractive dividend yield with a robust pipeline of growth opportunities backed by a low capital growth model. We reiterate our OUTPERFORM rating. (Published by Forsyth Barr)

F&P Healthcare (FPH) - Unmasking ResMed's 1Q21 Result

Competitor commentary and recent data points continue to reinforce the material tailwinds in FPH's Hospital segment. There is no change to our view that the 1H21 result (on 25 November) will be exceptional, and that the company's 'guide' for FY21 is conservative (our forecasts are already above this). FPH is a high-quality growth company and a material beneficiary of COVID-19. Earnings momentum is strong, although it becomes more challenging as consensus better reflects this. Nonetheless, COVID-19 is likely to continue to dominate the discussion near-term. We see better value growth stocks in both the NZ market and globally, albeit acknowledge momentum is on FPH's side while COVID-19 continues to be a factor globally. UNDERPERFORM. (Published by Forsyth Barr)

Freightways (FRE) — Parcels Tracking Higher

FRE issued a strong first quarter trading update driven by (1) double-digit parcel volume growth, (2) 'pricing for effort' gains, (3) cost initiatives in Information Management, (4) Big Chill acquisition accretion, and (5) a weak prior year comparative. We calculate like-for-like EPS (excluding the impact of an additional trading week) was up ~+27% against the prior year, which compares to current FY21 consensus EPS growth of +11%. FRE is trading at an attractive ~17x one year forward PE on our revised earnings estimates; this appears inconsistent with the improved growth prospects of the company. We reiterate our OUTPERFORM rating. (Published by Forsyth Barr)

Port of Tauranga (POT) — Covid Cargo Caution

POT reported a flat 1Q21 and highlighted near-term headwinds with subdued first time FY21 earnings guidance. First quarter trade cargo tonnage is down -5%, but with better margins, NPAT is broadly flat year on year. First time earnings guidance appears conservative, reflecting management's concerns over the consistency of cargo volumes and uncertainty over the broader global macro backdrop. With market earnings estimates above the top end of management's guidance band we expect negative earnings momentum to weigh on the shares in the near term. Moreover, with the valuation remaining elevated we retain an UNDERPERFORM rating. (Published by Forsyth Barr)

Z Energy (ZEL.NZ) — Trailing By Fifty (Percent) at Half Time

For the third year in a row, ZEL will report disappointing first half earnings, with COVID-19 decimating fuel volumes. Our 1H21 EBITDAF forecast of NZ$93m is close to half of the weak 1H20 result and is in the middle of ZEL's 1H21 guidance range of NZ$85m to NZ$100m. ZEL will not be paying an interim dividend and we would be surprised if it suggests anything other than a resumption of dividends at the 1H22 result, one year from now. Outlook commentary will be important and we expect ZEL to provide FY21 earnings guidance, albeit the range could be quite large. OUTPERFORM. (Published by Forsyth Barr)

Australia

Afterpay (APT.AX) — 1Q Trading Update – GMV slightly ahead, customer adds lower than expected

APT reported 1Q21 gross merchandise volume (GMV) of $4.1b, up +115% YoY and +9% QoQ, and in-line with Citi's estimate of $4.1b. However, customer net adds of 1.3m were lower than Citi's estimate of 1.5m, driven by the US. APT is on track to beat Citi's 1H21E GMV forecast of $8.8b (2Q implied $4.6b). However, Citi had expected a beat to its 1Q forecasts and given the recent strength in the share price, Citi sees potential for the share price to be down after the 1Q update. NEUTRAL. (Published by Citi)

Australia and New Zealand Banking Group (ANZ.AX) — An Abundance of Liquidity and Provisions

ANZ delivered FY20 cash earnings of $3,758m, matching consensus estimates ($3,767m). Credit quality indicators were positive. There was a strong improvement in deferred loans; risk-weighted asset migration estimates fell ~40%; and impaired assets fell. Citi has lowered its 3-year COVID-19 related loan loss provisions to 90bps from 106bps, of which 43bps was recognised in FY20. Consequently, Citi has raised its forward EPS by an average of ~10% and DPS by an average of ~16%. While asset quality was positive, core profit concerns were evident. ANZ remains a play on improving credit quality with some important milestones reached in this result. BUY. (Published by Citi)

Coles Group (COL.AX) — 1Q21 Sales Result — Moderating Sales and Slowing Costs

COL delivered Supermarket like-for-like (LFL) sales growth of +9.7% in 1Q21, in line with Citi's forecast of +9.4%. The focus of the trading update was on: 1) moderating COVID-19 costs; 2) slowing sales momentum; and 3) softening inflation. No earnings guidance was provided, however, LFL sales growth has peaked at +9.7% in 1Q21, moderating to +6.4% in October. Management expects a robust Christmas period with at-home entertaining to be strong given restrictions and cycling of NSW and VIC bushfires last year. Citi's price target reflects its positive view on grocery industry trends, which remains highly rational and continues to be a beneficiary of at-home consumption. BUY. (Published by Citi)

ResMed (RMD.AX) — Swifter recovery in sleep therapies

RMD's 1Q21 result was well ahead of UBS's (and consensus) forecast. Sleep-related sales (flow generators and masks) recovered faster than anticipated, and while still below last year's levels for flow generators, re-PAP and market share gains assisted in limiting the impact of fewer new set-ups. Ventilation sales associated with COVID-19 (~US$40m), while lower than 4Q20 levels, were ~US$13m ahead of UBS's forecast. SG&A cost control was again evident, with expenditure coming in -9% below UBS estimates. UBS forecasts continued strong revenue performance over the longer term, with operating leverage translating to +12% annualised EPS growth (FY19–23E). UBS upgraded its rating from NEUTRAL to BUY. (Published by UBS)

International

Gilead Sciences (GILD.O) — Could weak Remdesivir be the first clearing event for GILD stock?

While 3Q GILD numbers were ahead of expectations (product revenue grew +4.5% and EPS +10%), Remdesivir led to a reduction in guidance to $23–$23.5b from $23–$25b. Citi continues to see Remdesivir as a short-term story and believes the investment case at this point has to be based on the core business. Citi thinks this may be the time for a long-term investor to start thinking about GILD as it trades at 11x 2021 ex-Remdesivir EPS (10x including stock-based-compensation), but one would have to look past near-term margin contraction and EPS declines. BUY. (Published by Citi)

Microsoft (MSFT.O) — Strong Print, Mixed Guide

MSFT delivered strong revenue and EPS upside in the September quarter (1Q21) despite the tough economic backdrop, with Azure growth of 47% coming above mid-40% expectations. The December quarter outlook was more mixed, with revenue guidance of $40.0b (+8%) coming below the consensus estimate of $40.5b as the Gaming, Server Product and Windows outlooks fell short. UBS concluded that with EPS estimates moving up, the 10%+ top-line outlook intact and Azure growth 1–2 quarters away from stabilising, the stock set-up remains positive. BUY. (Published by UBS)

Calendar

Figure 4. Calendar

Date	New Zealand	Australia	International
2-Nov	Building Consents (Sep)	AIG Manufacturing Index (Oct)	UK: Manufacturing PMI (Oct)
		Manufacturing PMI	EU: German Manufacturing PMI (Oct)
		Melbourne Institute Inflation Gauge	CN: Manufacturing PMI (Oct)
		ANZ Job Advertisements	
		Building Approvals (Sep)	
		Home Loans	
		Westpac FY20	
3-Nov	NZ King Salmon AGM	RBA Interest Rates Decision (Nov)	JP: Culture Day Holiday
			US: ISM Manufacturing PMI (Oct)
			Estee Lauder 1Q20
			Bayer 3Q20
			Ferrari 3Q20
4-Nov	GlobalDairyTrade Price Index	AIG Construction Index	US: Presidential Election
	Employment Change (Q3)	Services PMI	UK: Composite PMI (Oct)
	Labour Cost Index (Q3)	RBA Chart Pack Release	UK: Services PMI (Oct)
	Participation Rate (Q3)	Retail Sales (Sep/Q3)	JP: BoJ Monetary Policy Statement
	Unemployment Rate (Q3)	Woolworths 1Q21 Sales	Humana 3Q20
	ANZ Commodity Price Index	Domino's Pizza AGM	
	Pushpay Holdings 1H21		
	Z Energy 1H21		
	NZ Oil & Gas AGM		
5-Nov	Trustpower 1H21	Trade Balance (Sep)	US: ADP Nonfarm Employment Change (Oct)
	Fonterra Co-operative Group AGM	National Australia Bank FY20	US: ISM Non-Manufacturing PMI (Oct)
	Marsden Maritime Holdings AGM	Coles Group AGM	US: Crude Oil Inventories
		Credit Corp AGM	UK: Services PMI
		Downer EDI AGM	UK: Construction PMI (Oct)
		James Hardie AGM	Qualcomm 4Q20
		Treasury Wines AGM	AstraZeneca 3Q20
			ING Groep 3Q20
6-Nov	Inflation Expectations	AIG Construction Index (Oct)	UK: BoE MPC Meeting Minutes
	Chorus AGM	AIG Services Index (Oct)	UK: BoE Interest Rate Decision
	Colonial Motors AGM	RBA Monetary Policy Statement	US: Initial Jobless Claims
	Spark AGM		US: Federal Reserve Interest Rate Decision
			US: FOMC Press Conference
			Alibaba 2Q21
			Bristol-Myers Squibb 3Q20
			Regeneron Pharmaceuticals 3Q20
7-Nov	CFTC NZD speculative net positions	CFTC AUD speculative net positions	US: Nonfarm Payrolls (Oct)
			US: Unemployment Rate (Oct)
			CVS Health 3Q20

Source: Forsyth Barr analysis

Analyst certification: For analyst certification relevant to any security recommendation in this report please refer to the most recent research report for that financial product.

Analyst holdings: For information about analyst holdings in a particular financial product referred to in this publication, please refer to the most recent research report for that financial product.

Disclosure: Forsyth Barr Limited and its related companies (and their respective directors, officers, agents and employees) ("Forsyth Barr") may have long or short positions or otherwise have interests in the financial products referred to in this publication, and may be directors or officers of, and/or provide (or be intending to provide) investment banking or other services to, the issuer of those financial products (and may receive fees for so acting). Forsyth Barr is not a registered bank within the meaning of the Reserve Bank of New Zealand Act 1989. Forsyth Barr may buy or sell financial products as principal or agent, and in doing so may undertake transactions that are not consistent with any recommendations contained in this publication. Other Forsyth Barr business units may hold views different from those in this publication; any such views will generally not be brought to your attention. Forsyth Barr confirms no inducement has been accepted from the issuer(s) that are the subject of this publication, whether pecuniary or otherwise, in connection with making any recommendation contained in this publication. In preparing this publication, non-financial assistance (for example, access to staff or information) may have been provided by the issuer(s) being researched.

Investment banking engagements: For information about whether Forsyth Barr has within the past 12 months been engaged to provide investment banking services to an issuer that is the subject of this publication, please refer to the most recent research report for that issuer's financial products.

Not personalised financial advice: The recommendations and opinions in this publication do not take into account your personal financial situation or investment goals. The financial products referred to in this publication may not be suitable for you. If you wish to receive personalised financial advice, please contact your Forsyth Barr Investment Adviser. The value of financial products may go up and down and investors may not get back the full (or any) amount invested. Past performance is not necessarily indicative of future performance. Disclosure statements for Forsyth Barr Investment Advisers are available on request and free of charge.

Disclaimer: This publication has been prepared in good faith based on information obtained from sources believed to be reliable and accurate. However, that information has not been independently verified or investigated by Forsyth Barr. Forsyth Barr does not make any representation or warranty (express or implied) that the information in this publication is accurate or complete, and, to the maximum extent permitted by law, excludes and disclaims any liability (including in negligence) for any loss which may be incurred by any person acting or relying upon any information, analysis, opinion or recommendation in this publication. Forsyth Barr does not undertake to keep current this publication; any opinions or recommendations may change without notice to you. Any analyses or valuations will typically be based on numerous assumptions; different assumptions may yield materially different results. Nothing in this publication should be construed as a solicitation to buy or sell any financial product, or to engage in or refrain from doing so, or to engage in any other transaction. This publication is not intended to be distributed or made available to any person in any jurisdiction where doing so would constitute a breach of any applicable laws or regulations or would subject Forsyth Barr to any registration or licensing requirement within such jurisdiction.